Ensysce Biosciences, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Ensysce Biosciences agreed to acquire Cy Biopharma in a two-step merger dated August 5, 2026. Merger consideration: 228,923 shares of Ensysce Convertible Preferred Stock (convertible into 228.923M shares of common stock at 1,000:1 ratio) plus 53,199 shares from convertible note conversions. Closing occurred simultaneously with signing. Company stockholders holding majority pre-approved merger via written consent and waived appraisal rights. Concurrent PIPE financing of $21.5M and convertible note financing support the transaction.
Why this rating
All-stock reverse merger fundamentally restructures Ensysce ($5.3M market cap); control shifts to Cy Biopharma shareholders. ~$229M equivalent consideration dwarfs acquirer; defines new direction. Transformational M&A for micro-cap company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.